Close

Daxor (DXR) Says Two New Studies Presented at HFSA Highlight Unique Ability of BVA to Identify High Risk Heart Failure Patients

Go back to Daxor (DXR) Says Two New Studies Presented at HFSA Highlight Unique Ability of BVA to Identify High Risk Heart Failure Patients

Daxor Corporation Announces Two New Studies From the Mayo Clinic and Lankenau Medical Center Presented at Heart Failure Society of America 2016 Highlight Unique Ability of BVA to Identify High Risk at

September 29, 2016 8:30 AM EDT

NEW YORK, NY -- (Marketwired) -- 09/29/16 -- Daxor Corporation (NYSE MKT: DXR), an investment company with medical instrumentation and biotechnology operations, announces two new studies presented at the Heart Failure Society of America meeting this month highlighting risks for hospitalized heart failure patients detectable by direct blood volume measurement (Daxor BVA-100).

Michael Feldschuh, President and CEO of Daxor, stated, "These new studies reinforce the outcomes presented earlier this year in the same arena showing the importance of direct blood volume analysis for improving heart failure results. It is only with the unique... More